3 completed, 1 active not recruiting, 1 unknown. 2 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Prothionamide: new trials by email Literature Review of Prothionamide trials Research Report on Prothionamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort Bedaquiline, Delamanid, Contezolid - Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis | Phase 3 | Active not recruiting | Beijing Chest Hospital | 186 | 2023-12-22 | 2025-04-01 |
| A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China Bedaquiline, Levofloxacin, Linezolid - Tuberculosis, Multidrug-Resistant | Phase 4 | Unknown | Beijing Chest Hospital | 212 | 2022-05-10 | 2023-01-18 |
| The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline), Moxifloxacin, Clofazimine - MDR-TB | Phase 3 | Completed | IUATLD, Inc | 588 | 2016-03-01 | 2023-09-28 |
| Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents Levofloxacin and Streptomycin added, Moxifloxacin and Kanamycin added - Healthy | Phase 1 | Completed | Seoul National University Hospital | 16 | 2013-11-01 | 2014-05-01 |
| Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2 - HIV Infections | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1578 | 2003-06-09 | 2025-12-02 |
Tuberculosis, Multidrug-Resistant (2) · HIV Infections (1) · Tuberculosis (1) · Tuberculosis, Pulmonary (1)
Beijing Chest Hospital (2) · IUATLD, Inc (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Seoul National University Hospital (1)
China (2) · South Africa (2) · Argentina (1) · Botswana (1) · Brazil (1) · Ethiopia (1) · Georgia (1) · India (1) · Moldova (1) · Mongolia (1) · Puerto Rico (1) · South Korea (1) · Tanzania (1) · Thailand (1) · Uganda (1)
Andrew Nunn, PhD (1) · Mark Mirochnick, MD (1) · Mengqiu Gao (1) · Sarah Meredith, MD (1)
PMID 16470119, PMID 16988514, PMID 18366444, PMID 18795962, PMID 18989231, PMID 20002783, PMID 20632458, PMID 21283017, PMID 22083071, PMID 22129166, PMID 23305215, PMID 23392467, PMID 25162818, PMID 25261418, PMID 25407158, PMID 25950206, PMID 25959631, PMID 25987620, PMID 26202768, PMID 26918544, PMID 26929418, PMID 27540363, PMID 29369162, PMID 29520730, PMID 29528944, PMID 30134297, PMID 30358179, PMID 30530925, PMID 30715324, PMID 30865791, PMID 31489678, PMID 32015036, PMID 32451908, PMID 33252495, PMID 33318014, PMID 34076612, PMID 34732682, PMID 38462751, PMID 38561815, PMID 40741959, PMID 41925982, PMID 42828638